AUTHOR=Caruso Cristiano , Cameli Paolo , Altieri Elena , Aliani Maria , Bracciale Pietro , Brussino Luisa , Caiaffa Maria Filomena , Canonica Giorgio Walter , Centanni Stefano , D’Amato Maria , Del Giacco Stefano , De Michele Fausto , Pastorello Elide Anna , Pelaia Girolamo , Rogliani Paola , Romagnoli Micaela , Schino Pietro , Caminati Marco , Vultaggio Alessandra , Zullo Alessandro , Rizzoli Sara , Boarino Silvia , Vitiello Gianfranco , Menzella Francesco , Di Marco Fabiano TITLE=Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis JOURNAL=Frontiers in Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.950883 DOI=10.3389/fmed.2022.950883 ISSN=2296-858X ABSTRACT=Background

Severe asthma is a heterogeneous inflammatory disease driven by eosinophilic inflammation in the majority of cases. Despite biologic therapy patients may still be sub-optimally controlled, and the choice of the best biologic is a matter of debate. Indeed, switching between biologics is common, but no official guidelines are available and real-world data are limited.

Materials and methods

In this post hoc analysis of the Italian, multi-center, observational, retrospective study, ANANKE. Patients with severe eosinophilic asthma treated with benralizumab were divided in two groups based on history of previous biologic therapy (biologic-experienced [suboptimal response] vs naïve). Baseline clinical and laboratory characteristics were collected in the 12 months prior to benralizumab treatment. Change over time in blood eosinophils, annualized exacerbation rate (AER), asthma control (ACT), lung function and oral corticosteroid (OCS) use following benralizumab initiation were collected in the two groups.

Results

A total of 147 biologic-naïve and 58 biologic-experienced (34 omalizumab, 19 mepolizumab, and 5 omalizumab-mepolizumab) patients were enrolled. Biologic-experienced patients were more likely to be atopic and have a higher AER despite more frequent OCS use. Similar reductions in AER (>90% in both groups), OCS use (≥49% reduction in dosage and ≥41% able to eliminate OCS), ACT improvement (≥7 points gained in 48 weeks) and lung function (≥300 mL of FEV1 improvement in 48 weeks) were observed after benralizumab introduction within the two groups. There were no registered discontinuations of benralizumab for safety reasons.

Conclusion

In this post hoc analysis, patients who were switched to benralizumab because of suboptimal control with a previous biologic therapy were more likely to be atopic and more often treated with omalizumab. Benralizumab is effective in both naïve patients and those previously treated with a biologic.